UBS Group’s Tevogen Bio Holdings TVGN Stock Holding History

UBS Group’s Portfolio TVGN Stock Details TVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.1K	Buy	3,567 +2,469	+225%	+$30.3K	﹤0.01%	8084
2025 Q4	$18.2K	Buy	1,098 +280	+34%	+$7.28K	﹤0.01%	7855
2025 Q3	$32.1K	Sell	818 -804	-50%	-$39.5K	﹤0.01%	7849
2025 Q2	$101K	Sell	1,622 -2,055	-56%	-$117K	﹤0.01%	7228
2025 Q1	$199K	Sell	3,677 -15	-0.4%	-$987	﹤0.01%	6567
2024 Q4	$190K	Buy	3,692 +3,480	+1,642%	+$227K	﹤0.01%	6479
2024 Q3	$3.89K	Buy	212 +79	+59%	+$2.31K	﹤0.01%	8206
2024 Q2	$4.8K	Buy	+133	New	+$8.67K	﹤0.01%	8050
2023 Q4	–	Sell	-3	Closed	-$1.59K	–	9978
2023 Q3	$1.59K	Buy	+3	New	+$1.62K	﹤0.01%	7885
2023 Q2	–	Sell	-14	Closed	-$7.76K	–	9779
2023 Q1	$7.76K	Buy	14 +12	+600%	+$6.37K	﹤0.01%	7778
2022 Q4	$1.03K	Sell	2 -2	-50%	-$1.02K	﹤0.01%	9982
2022 Q3	$2K	Hold	4	–	–	﹤0.01%	9792
2022 Q2	$2K	Buy	+4	New	+$2K	﹤0.01%	9634

Other funds holding TVGN

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

UBS Group's TVGN Position: Q1 2026 in Review

UBS Group increased its Tevogen Bio Holdings (TVGN) stake by 225% in Q1 2026, buying an estimated $30.3K and bringing the position to 3,567 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #8084.

UBS Group first reported a position in TVGN in Q2 2022 and has held it in 13 quarters since. The position peaked at $199K in Q1 2025. 30 funds tracked by Wall St. Rank hold TVGN as of Q1 2026.

UBS Group held 3,567 shares of Tevogen Bio Holdings worth $16.1K as of Q1 2026.
UBS Group bought 2,469 Tevogen Bio Holdings shares in Q1 2026, an estimated $30.3K.
Tevogen Bio Holdings made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8084 holding.
UBS Group first reported a position in Tevogen Bio Holdings in Q2 2022 and has held it in 13 quarters since.
UBS Group's Tevogen Bio Holdings position peaked at $199K in Q1 2025.
30 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.